Ventracor sees bright future despite losses
This article was originally published in Clinica
Executive Summary
High expenditure on regulatory activities laid a significant dent in Ventracor's coffers, as the Australian developer of the VentrAssist left ventricle assist device recorded net loss of $36.5m for the year 2006/07. As it strives to expand its coverage in key international markets, the company said it spent heavily on guiding its lead technology through regulatory approvals in the US, Europe and Australia, but hopes to become profitable in the near future.